Overview

A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Status:
Recruiting

Trial end date:
2023-08-10

Target enrollment:

Participant gender:

Summary

This study will consider the safety and effectiveness of a study drug, CAN04, in combination with FOLFIRINOX, in the treatment of metastatic pancreatic ductal adenocarcinoma.

Phase:

Phase 1

Details

Lead Sponsor:

Cantargia AB

Treatments:

Folfirinox